Deutsche Bank Research has reduced Novartis' price target from 140 to 120 Swiss francs and downgraded its stock from 'Buy' to 'Hold'. Emmanuel Papadakis, in his assessment released on Wednesday, noted that the pharmaceutical giant has suffered another setback with the failure of the heart and circulatory system medication Del-desiran. While this product carries less commercial weight and has not significantly impacted analyst estimates, the failure serves as a critical test for the rationale behind Novartis' 12 billion dollar acquisition of Avidity, the manufacturer of Del-desiran, particularly in light of the upcoming patent expirations for Cosenty, Kisqali, and Kesimpta in the early 2030s.
The failure of Del-desiran underscores the challenges Novartis faces in maintaining its market position as patent protections for its key products begin to expire. The acquisition of Avidity was a strategic move to extend the commercial life of these products, but the recent setback could cast doubt on the long-term viability of this strategy.
The report highlights the broader implications for the pharmaceutical industry, where companies are increasingly focusing on extending the commercial life of their products through acquisitions and innovative strategies. However, the success of such strategies depends on the ability to deliver on the promises made and to navigate the complexities of the market environment.
